Last updated: February 14, 2026
Overview
NDC 47335-0506 corresponds to evenity (romosozumab-aqqg), marketed by Amgen. It is a monoclonal antibody indicated for osteoporosis treatment in postmenopausal women at high risk of fracture. Approved by the FDA in April 2019, it generated initial interest owing to its dual mechanism: promoting bone formation while decreasing bone resorption.
Market Landscape
- The global osteoporosis market was valued at approximately $10 billion in 2022.
- Key competitors include bisphosphonates (e.g., alendronate), denosumab (Prolia), teriparatide, and abaloparatide.
- Romosozumab captured early market share due to its novel dual action, but faced restrictions after safety concerns.
Regulatory and Safety Factors
- The FDA issued a boxed warning for increased risk of cardiovascular events observed during clinical trials.
- The European Medicines Agency (EMA) suspended approval in some markets over safety concerns but later resumed approvals with restrictions.
- These safety signals have limited widespread adoption, particularly among patients with cardiovascular risk factors.
Market Adoption and Prescribing Trends
- As of 2023, romosozumab remains a niche treatment, with an estimated 3-4% market share among osteoporosis treatments in the US.
- Prescriptions are concentrated within specialized centers; general osteoporotic population remains primarily treated with bisphosphonates.
- Innovator's pricing set at approximately $1,600 per dose (monthly), with a typical course involving 12 injections.
Price Projections
| Year |
Price per Dose |
Assumed Annual Cost |
Market Penetration |
Revenue Estimate |
| 2023 |
$1,600 |
$19,200 |
3-4% of 7 million US osteoporotic patients |
$200 million |
| 2024 |
$1,600 |
$19,200 |
Slight increase in adopters |
$250 million |
| 2025 |
$1,600 |
$19,200 |
Stabilization or slight decrease due to pricing pressure |
$250 million |
Pricing Dynamics
- Price sensitivity remains high due to safety concerns, reimbursement hurdles, and competition.
- No significant discounts or biosimilar entrants are imminent; pricing stability expected over next 2-3 years.
- Potential for negotiated discounts through insurance or Medicaid plans could reduce net revenue by 10-15%.
Pricing Comparatives
- Denosumab (Prolia): Approximate list price $1,300 per dose, annual spend about $1,560.
- Teriparatide (Forteo): Approximate list price $4,200/month, totaling around $50,400 annually.
- Bisphosphonates: Often generic, around $50 annually.
Romosozumab's higher price reflects its novel mode but may inhibit rapid growth.
Regulatory and Market Barriers Impact
- Safety signals have tempered enthusiasm and hinder broader prescribing.
- Future market expansion depends on safety data, head-to-head comparative efficacy, and evolving guidelines.
- Potential for biosimilar development remains limited due to patent protections and manufacturing complexities.
Conclusion
Market size for romosozumab remains constrained. Its high cost combined with safety concerns restricts rapid, widespread adoption. Price stability is forecasted over 2-3 years, with potential declines driven by payer negotiations. Revenue projections reflect a niche but steady presence in the osteoporosis treatment segment.
Key Takeaways
- NDC 47335-0506 (romosozumab) faces a limited market due to safety concerns, with current market share below 5%.
- The drug is priced around $1,600 per injection, with little imminent price change.
- Competition from established bisphosphonates and denosumab limits market growth.
- Future sales depend heavily on safety profile elucidation and insurance reimbursement policies.
- No biosimilars are expected soon, conserving current pricing structures.
Frequently Asked Questions
1. Will romosozumab's price decrease in the next 2 years?
Likely. Payer negotiations, safety concerns, and competitive pressures may drive discounts or formulary restrictions.
2. Can safety concerns significantly restrict market growth?
Yes. Increased safety warnings and regulatory actions can limit prescribing to high-risk populations, reducing overall sales.
3. Are biosimilars in development for romosozumab?
Not currently. Patent protections and manufacturing complexity delay biosimilar entry, maintaining current pricing.
4. How does romosozumab compare to denosumab in cost?
Romosozumab is more expensive ($1,600 vs. ~$1,300 per dose), and its use is more limited by safety considerations.
5. What factors influence future revenue projections?
Safety data, regulatory decisions, reimbursement policies, and clinical guidelines will be decisive.
References
[1] IQVIA. "Global Osteoporosis Market Report," 2022.
[2] FDA. "FDA Approves New Treatment for Postmenopausal Women at High Risk for Fracture," April 2019.
[3] European Medicines Agency. "Assessment of Romosozumab," 2020.
[4] Amgen. "Product Information and Pricing Data," 2023.
